Upfront autologous stem cell transplantation (ASCT) Vs carfilzomib-cyclophosphamide-dexamethasone (KCD) consolidation in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM): results of the cardamon study according to cytogenetic risk
Authors
Yong, K.Wilson, W.
Camilleri, M.
Ramasamy, K.
Streetly, M.
Sive, J.
Bygrave, C. A.
Chapman, M.
de Tute, R. M.
Chavda, S. J.
Phillips, Elizabeth H
Cuadrado, M. D. M.
Pang, G.
Jenner, R.
Dadaga, T.
Kamora, S.
Cavenagh, J.
Clifton-Hadley, L.
Owen, R. G.
Popat, R.
Affiliation
Cancer Institute, Department of Haematology, University College London, London, United KingdomIssue Date
2021
Metadata
Show full item recordCitation
Yong K, Wilson W, Camilleri M, Ramasamy K, Streetly M, Sive J, et al. Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413903204.Journal
BloodDOI
10.1182/blood-2021-147771Additional Links
https://dx.doi.org/10.1182/blood-2021-147771Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-147771